Physician profile
Richard Stefanacci
NPI 1689748600
$145,825.36
in general payments reported to CMS, 2019-2025
19 companies · $13K in 2025
The $13K reported for 2025 was more than what 98% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $8,080 · 2021: $21K · 2022: $16K · 2023: $19K · 2024: $18K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,313 · Travel and Lodging: $2,826 · Honoraria: $1,200 · Food and Beverage: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,007.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,477.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,312.50 |
| Travel and Lodging | $2,825.97 |
| Honoraria | $1,200.00 |
| Food and Beverage | $285.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30,712.50 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $20,201.95 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $19,781.44 | 2019 | |
| Urovant Sciences INC | $18,023.28 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $10,314.91 | 2021-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $8,045.70 | 2023 | Austedo Xr |
| Genentech USA, INC. | $7,506.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $6,348.00 | 2021-2022 | |
| Pfizer INC. | $5,053.94 | 2019-2025 | |
| Ucb, INC. | $4,400.00 | 2023 | |
| Sumitomo Pharma America, INC. | $4,043.96 | 2023 | Gemtesa |
| Fisher Scientific Company L.L.C. | $3,700.00 | 2022-2023 | Procalcitonin |
| Eisai INC. | $2,925.00 | 2020 | |
| Otter Pharmaceuticals, LLC | $1,491.00 | 2025 | Sympazan |
| Biogen, INC. | $1,155.00 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $1,027.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $720.00 | 2019 | |
| Acadia Pharmaceuticals INC | $360.16 | 2019 | |
| Glaxosmithkline, LLC. | $15.10 | 2024 | Arexvy, Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Stefanacci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.